Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings

Curr HIV/AIDS Rep. 2016 Apr;13(2):116-24. doi: 10.1007/s11904-016-0308-x.

Abstract

The past 3 years have marked a transition from research establishing the safety and efficacy of HIV preexposure prophylaxis (PrEP) to questions about how to optimize its implementation. Until recently, PrEP was primarily offered as part of randomized controlled trials or open-label studies. These studies highlighted the key components of PrEP delivery, including regular testing for HIV and other sexually transmitted infections (STIs), adherence and risk-reduction support, and monitoring for renal toxicity. PrEP is now increasingly provided in routine clinical settings. This review summarizes models for PrEP implementation from screening through initiation and follow-up, focusing on the strengths and weaknesses of three delivery systems: a health maintenance organization, an STI clinic, and a primary care practice. These early implementation experiences demonstrate that PrEP can be successfully delivered across a variety of settings and highlight strategies to streamline PrEP delivery in clinical practice.

Keywords: Delivery of health care; Human immunodeficiency virus (HIV); Implementation; PrEP delivery; PrEP implementation; Preexposure prophylaxis (PrEP); Review; Science of prevention; Sexually transmitted infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Ambulatory Care Facilities
  • Anti-HIV Agents / therapeutic use*
  • Delivery of Health Care
  • Emtricitabine / therapeutic use*
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control*
  • Health Maintenance Organizations
  • Humans
  • Pre-Exposure Prophylaxis / methods*
  • Primary Health Care
  • Risk Reduction Behavior
  • Tenofovir / therapeutic use*

Substances

  • Anti-HIV Agents
  • Tenofovir
  • Emtricitabine